O3–06–05: Sustained cognitive benefit in patients with mild cognitive impairment (MCI) upon prolonged treatment with CHF5074Joel Ross, Bruno P. Imbimbo, Gabriella Bottini et al.|Alzheimer s & Dementia|2013Cited by 3
P1‐269: A 12‐week, double‐blind, placebo‐controlled, dose‐range finding study of CHF5074 in patients with mild cognitive impairmentJoel Ross, Bruno P. Imbimbo, Sanjiv Sharma et al.|Alzheimer s & Dementia|2012Cited by 0